Etoricoxib

규격

202409-33-4CAS 번호

682-421-5EC 번호

5-chloro-2-(6-methyl-3-pyridinyl)-3-(4-methylsulfonylphenyl)pyridineIUPAC 명칭

C18H15ClN2O2S화학식

358.8 g/mol분자량

Etoricoxib; 202409-33-4; Arcoxia; MK-0663; 5-Chloro-6'-methyl-3-(4-(methylsulfonyl)phenyl)-2,3'-bipyridine; 5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl)pyridine; L-791456; 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-2,3'-bipyridine; DTXSID3046457; etoricoxibum; MK0663; 2,3'-Bipyridine, 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-; WRX4NFY03R; L791456; 5-Chloro-6'-methyl-3-(p-(methylsulfonyl)phenyl)-2,3'-bipyridine; 2,3'-Bipyridine, 5-chloro-6'-methyl-3-(4-(methylsulfonyl)phenyl)-; CHEBI:6339; DTXCID1026457; 5-chloro-2-(6-methylpyridin-3-yl)-3-(4-(methylsulfonyl)phenyl)pyridine; 5-Chloro-3-(4-methanesulfonyl-phenyl)-6'-methyl-[2,3']bipyridinyl; 5-chloro-3-(4-methanesulfonylphenyl)-2-(6-methylpyridin-3-yl)pyridine; 5-Chloro-3-(4-methanesulfonyl-phenyl)-6'-methyl-(2,3')bipyridinyl; RefChem:388965; L 791456; M01AH05; 5-Chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl) Pyridine; Tauxib; Nucoxia; Algix; MK-663; MK 0663; MFCD06797512; CHEMBL416146; C18H15ClN2O2S; Etropain; Torcoxia; Etoxib; NCGC00164578-01; Etoricoxibe; Kingcox; MK-0663;L-791456; Etoricoxib [USAN:INN:BAN]; MK 663; Etoricoxib [USAN]; CAS-202409-33-4; SR-05000001486; Etoricoxib (USAN/INN); UNII-WRX4NFY03R; Etoricoxib?; Etoricoxib (Standard); ETORICOXIB [MI]; ETORICOXIB [INN]; ETORICOXIB [MART.]; SCHEMBL4680; ETORICOXIB [WHO-DD]; Etoricoxib - Bio-X trade mark; GTPL2896; orb1225746; orb1308128; orb3025561; SCHEMBL29366203; SCHEMBL29402456; SCHEMBL30988052; MSK8006; GLXC-08166; HMS2090A05; HMS3713P20; HMS3885H14; HMS5083M08; 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-2,3'-bipyridine; EX-A2642; Tox21 112206; Tox21_112206; 5-chloro-2-(6-methyl-3-pyridyl)-3-(4-methylsulfonylphenyl)pyridine; 5-Chloro-6'-methyl-3-(4-(methylsulfonyl)-phenyl)-2,3'-bipyridine; BDBM50072064; EBC-00675; Etoricoxib; MK-663; MK-0663; HY-15321R; MSK8006-100A; s4651; AKOS016010125; Tox21_112206_1; CCG-220639; DB01628; FC23204; SB18988; NCGC00164578-02; NCGC00164578-05; 5CH; AC-29052; AS-17761; BC164436; HY-15321; SY111379; DB-045133; E7858; NS00005633; D03710; Etoricoxib Solution in Acetonitrile, 100ug/mL; Etoricoxib, VETRANAL(TM), analytical standard; AB01275483-01; EN300-18530864; L001141; Q631202; SR-05000001486-1; SR-05000001486-2; BRD-K54770957-001-01-9; BRD-K54770957-001-02-7; BRD-K54770957-001-04-3; F2173-0490; Z2216907255; Etoricoxib, United States Pharmacopeia (USP) Reference Standard; 5-Chloro-3-[4-(methanesulfonyl)phenyl]-6'-methyl-2,3'-bipyridine; 5-chloro-2-(6-methyl-3-pyridinyl)-3-(4-methylsulfonylphenyl)pyridine; 5-Chloro-3-(4-methanesulfonyl-phenyl)-6''''-methyl-[2,3'''']bipyridinyl; 5-Chloro-3-(4-methanesulfonyl-phenyl)-6''-methyl-[2,3'']bipyridinyl; 5-chloro-6''-methyl-3-[4-(methylsulfonyl)phenyl]-2,3''-bipyridine; 5-Chloro-6 inverted exclamation mark -methyl-3-[4-(methylsulfonyl)phenyl]-2,3 inverted exclamation mark -bipyridine동의어